Coral Laboratories Quarterly Results for Trading Insights
In March 2026, Coral Laboratories (CORALAB) reported revenue ₹86 Cr and net profit ₹17 Cr — revenue -30.6% YoY. Browse CORALAB complete financial statements for revenue, profit, balance sheet and cash flow data.
CORALAB Quarterly Results — Revenue, Profit & EPS Highlights
Coral Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore CORALAB share price data to track price trends across different timeframes.
- Revenue of ₹86 Cr in March 2026 (-30.6% vs March 2025, -30.6% vs March 2025)
- Net Profit of ₹17 Cr in March 2026 (-29.2% vs March 2025, -29.2% vs March 2025)
- EBITDA of ₹15 Cr in March 2026 (-57.1% vs March 2025)
- Operating Margin of 18.0% in March 2026 (-5.0pp vs March 2025)
- Earnings Per Share of ₹45.85 in March 2026 (-32.2% vs March 2025)
Coral Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CORALAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 86 | 124 | 90 | 85 | 80 | -30.6% | -30.6% |
| Net Profit (₹ Cr) | 17 | 24 | 16 | 6 | 9 | - | - |
| EBITDA (₹ Cr) | 15 | 35 | 23 | 11 | 13 | - | - |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | - | - |
| Operating Margin (%) | 18.0% | 23.0% | 19.0% | 5.0% | 11.0% | - | - |
CORALAB Share Price Trend — 1-Year Movement Across Quarterly Results
Coral Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Coral Laboratories share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CORALAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Coral Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹477,587.63 Cr | 1940.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 171.7 |
|
Divis Laboratories
Mar 2026 |
₹227,904.78 Cr | 8388.0 | 2,986 | 751 | -5.0% | - | 25.2% | 296.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 5000.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 434.4 |
|
Cipla
Mar 2026 |
₹117,848.47 Cr | 1458.8 | 6,612 | 543 | -9.3% | - | 8.2% | 212.3 |
|
Zydus Life Science
Mar 2026 |
₹112,798.83 Cr | 1121.1 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 88.6 |
All amounts in ₹ Crores